593 related articles for article (PubMed ID: 27353055)
21. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.
Taneja S; Tohra S; Duseja A; Dhiman RK; Chawla YK
J Clin Exp Hepatol; 2016 Dec; 6(4):282-290. PubMed ID: 28003717
[TBL] [Abstract][Full Text] [Related]
22. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
Yu ML; Lin SM; Lee CM; Dai CY; Chang WY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Liaw YF
Hepatology; 2006 Nov; 44(5):1086-97. PubMed ID: 17058238
[TBL] [Abstract][Full Text] [Related]
23. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
[TBL] [Abstract][Full Text] [Related]
24. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
26. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
27. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
28. Non-invasive assessment of liver fibrosis in chronic viral hepatitis.
Orasan OH; Iancu M; Sava M; Saplontai-Pop A; Cozma A; Sarlea ST; Lungoci C; Ungureanu MI; Negrean V; Sampelean D; Dumitrascu DL
Eur J Clin Invest; 2015 Dec; 45(12):1243-51. PubMed ID: 26426402
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Deltenre P; Corouge M; Canva V; Castel H; Wartel F; Dharancy S; Louvet A; Lazrek M; Moreno C; Henrion J; Mathurin P
J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting.
Lesmana CR; Salim S; Hasan I; Sulaiman AS; Gani RA; Pakasi LS; Lesmana LA; Krisnuhoni E; Budihusodo U
J Clin Pathol; 2011 Oct; 64(10):916-20. PubMed ID: 21670074
[TBL] [Abstract][Full Text] [Related]
31. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
[TBL] [Abstract][Full Text] [Related]
33. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.
Wang CC; Liu CH; Lin CL; Wang PC; Tseng TC; Lin HH; Kao JH
J Formos Med Assoc; 2015 Oct; 114(10):923-8. PubMed ID: 26279173
[TBL] [Abstract][Full Text] [Related]
34. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
35. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
36. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
[TBL] [Abstract][Full Text] [Related]
37. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
Estrabaud E; Lapalus M; Broët P; Appourchaux K; De Muynck S; Lada O; Martinot-Peignoux M; Bièche I; Valla D; Bedossa P; Marcellin P; Vidaud M; Asselah T
J Virol; 2014 Jun; 88(11):6394-402. PubMed ID: 24672032
[TBL] [Abstract][Full Text] [Related]
38. Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.
Deghady A; Abdou A; El-Neanaey WA; Diab I
Genet Test Mol Biomarkers; 2012 Jun; 16(6):531-5. PubMed ID: 22352690
[TBL] [Abstract][Full Text] [Related]
39. Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver.
Lannerstedt H; Konopski Z; Sandvik L; Haaland T; Løberg EM; Haukeland JW
Scand J Gastroenterol; 2013 Jan; 48(1):93-100. PubMed ID: 23205894
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.
Ragazzo TG; Paranagua-Vezozzo D; Lima FR; de Campos Mazo DF; Pessoa MG; Oliveira CP; Alves VAF; Carrilho FJ
Clinics (Sao Paulo); 2017 Oct; 72(9):516-525. PubMed ID: 29069254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
